Steroid 5 alpha-reductase 3 (SRD5A3) promotes tumor growth and predicts poor survival of human hepatocellular carcinoma (HCC)

Qicong Mai; Dafeng Sheng; Chengcong Chen; Qing Gou; Meng Chen; Xiaoting Huang; Heng Yin; Xiaoming Chen; Zide Chen

doi:doi:10.18632/aging.104142

← Back

Research Paper Volume 12, Issue 24 pp 25395—25411

Steroid 5 alpha-reductase 3 (SRD5A3) promotes tumor growth and predicts poor survival of human hepatocellular carcinoma (HCC)

Figure 4. The expression of SRD5A3 is correlated with the clinical stage and the gender of HCC patients. In the TCGA(LIHC) dataset, the correlation between (A) clinical stage, (B) vascular invasion, (C) gender, and SRD5A3 expression was analyzed in HCC patients with clinical data. LIHC, liver hepatocellular carcinoma (HCC).